Evidence map›Paper›PMID 31759978›Full record

ArticleBiochemical pharmacology2020

JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells.

K A Heslop, A Rovini, E G Hunt, D Fang, M E Morris, C F Christie, M B Gooz, D N DeHart, Y Dang, J J Lemasters and 1 more

Open access · greenAbstract read
In one paragraph

Article in Biochemical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Mechanisms of Location Bias in G Protein-Coupled Receptors.Handbook of experimental pharmacology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Mitochondrial Kinase Signaling for Cardioprotection.International journal of molecular sciences · 2024
    Review
  13. Mitochondrial P-JNK target, SAB (SH3BP5), in regulation of cell death.Frontiers in cell and developmental biology · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

K A HeslopDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
A RoviniDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
E G HuntDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
D FangDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
M E MorrisDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
C F ChristieDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
M B GoozDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
D N DeHartDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States.
Y DangDepartment of Medicine, Medical University of South Carolina, Charleston, SC, United States.
J J LemastersDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States; Department of Biochemistry & Molecular Biology, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.
E N MaldonadoDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC, United States; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States. Electronic address: maldona@musc.edu.
Medical University of South Carolina · US

Funding

SOUTH CAROLINA COBRE IN OXIDANTS, REDOX BALANCE AND STRESS SIGNALINGP20GM103542 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI TEW, KENNETH D. · 2012 to 2020
$20.2M
MUSC Minority Student Development ProgramR25GM072643 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ERGUL, ADVIYE, RINKER, JENNIFER ANNE · 2005 to 2023
$5.8M
MUSC Post-Baccalaureate Research Education ProgramR25GM113278 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DELEON-PENNELL, KRISTINE Y, PENROD-MARTIN, RACHEL · 2015 to 2024
$2.7M
VDAC-Tubulin Regulation of Mitochondrial Membrane Potential HeterogeneityR01CA184456 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI MALDONADO, EDUARDO NESTOR · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA184456NIGMS NIH HHS P20 GM103542NIGMS NIH HHS R25 GM072643NIGMS NIH HHS R25 GM113278
6 · The paper itself

Abstract

The multikinase inhibitor sorafenib, and opening of voltage dependent anion channels (VDAC) by the erastin-like compound X1 promotes oxidative stress and mitochondrial dysfunction in hepatocarcinoma cells. Here, we hypothesized that X1 and sorafenib induce mitochondrial dysfunction by increasing reactive oxygen species (ROS) formation and activating c-Jun N-terminal kinases (JNKs), leading to translocation of activated JNK to mitochondria. Both X1 and sorafenib increased production of ROS and activated JNK. X1 and sorafenib caused a drop in mitochondrial membrane potential (ΔΨ), a readout of mitochondrial metabolism, after 60 min. Mitochondrial depolarization after X1 and sorafenib occurred in parallel with JNK activation, increased superoxide (O

Indexed as

AnthracenesAntineoplastic AgentsCarcinoma, HepatocellularCell DeathCell Line, TumorEnzyme ActivationHep G2 CellsHumansJNK Mitogen-Activated Protein KinasesLiver NeoplasmsMembrane Potential, MitochondrialMitochondriaOxidative StressProtein TransportReactive Oxygen SpeciesSorafenibAnthracenesAntineoplastic AgentsJNK Mitogen-Activated Protein KinasespyrazolanthroneReactive Oxygen SpeciesSorafenibVoltage-Dependent Anion ChannelsHepatocarcinomaJNKMitochondriaMitochondrial membrane potentialROSSabSorafenibVDAC

Identifiers

PMID31759978
PMCPMC7309270
OpenAlexW2991543716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.